Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Julie J. Miller, Ph.D., M.D.


Stanford University School of Medicine, Palo Alto, CAMD06/2011Medicine
Stanford University School of Medicine, Palo Alto, CAPhD06/2011Cancer Biology
Stanford University School of Medicine, Palo Alto, CA06/2012Internship in Medicine
Partners Neurology - Massachusetts General Hospital/Brigham and Women's Hospital, Boston, MA06/2015Neurology Residencey
Massachusetts General Hospital/Dana-Farber Cancer Institute, Boston, MA06/2018Neuro-Oncology Fellowship

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. ACS-IRG (MILLER, JULIE) Jan 1, 2022 - Dec 31, 2022
    American Cancer Society
    Targeting the CDK-Rb pathway in recurrent IDH-mutant glioma
    Role: Principle Investigator
  2. U19CA264504 (BATCHELOR, TRACY T) Sep 21, 2021 - Aug 31, 2026
    Harvard/Stanford GTN Program: Novel targeted therapeutics for glioblastoma
    Role: Co-Investigator
  3. K08NS119796 (MILLER, JULIE) Aug 1, 2021 - Jul 31, 2026
    Investigation of Sirt1 activation to target IDH mutant glioma
    Role: Principal Investigator
  4. Neurology Transformative Scholar (MILLER, JULIE) Jul 1, 2020 - Dec 31, 2022
    MGH Department of Neurology
    Investigation of caloric restriction as a therapeutic target for IDH mutant glioma
    Role: Principle Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Miller JJ, Arrillaga-Romany I. IDH-mutant glioma: A new IDH1 inhibitor moves forward. Neuro Oncol. 2023 02 14; 25(2):337-338. PMID: 36526609; PMCID: PMC9925702.
    Citations:    Fields:    Translation:Humans
  2. Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS, Bi WL, Bindra R, Cahill DP, Chang SM, Costello JF, Horbinski C, Huang RY, Jenkins RB, Ligon KL, Mellinghoff IK, Nabors LB, Platten M, Reardon DA, Shi DD, Schiff D, Wick W, Yan H, von Deimling A, van den Bent M, Kaelin WG, Wen PY. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023 01 05; 25(1):4-25. PMID: 36239925; PMCID: PMC9825337.
    Citations: 2     Fields:    Translation:Humans
  3. Numan T, Breedt LC, Maciel BAPC, Kulik SD, Derks J, Schoonheim MM, Klein M, de Witt Hamer PC, Miller JJ, Gerstner ER, Stufflebeam SM, Hillebrand A, Stam CJ, Geurts JJG, Reijneveld JC, Douw L. Regional healthy brain activity, glioma occurrence and symptomatology. Brain. 2022 10 21; 145(10):3654-3665. PMID: 36130310; PMCID: PMC9586543.
    Citations: 4     Fields:    Translation:Humans
  4. Miller JJ, Cahill DP, Arrillaga-Romany I. Enhancing demethylation-induced differentiation in IDH-mutant glioma. Neuro Oncol. 2022 05 04; 24(5):724-725. PMID: 35239963; PMCID: PMC9071324.
    Citations:    Fields:    Translation:HumansCells
  5. Miller JJ. Targeting IDH-Mutant Glioma. Neurotherapeutics. 2022 10; 19(6):1724-1732. PMID: 35476295; PMCID: PMC9723039.
    Citations: 1     Fields:    Translation:Humans
  6. Miller JJ, Wang N. Body imaging for newly diagnosed CNS lymphoma: Evaluating the utility of the evaluation. Neuro Oncol. 2022 03 12; 24(3):492-493. PMID: 35020930; PMCID: PMC8917389.
    Citations:    Fields:    Translation:Humans
  7. Richardson LG, Miller JJ, Kitagawa Y, Wakimoto H, Choi BD, Curry WT. Implications of IDH mutations on immunotherapeutic strategies for malignant glioma. Neurosurg Focus. 2022 02; 52(2):E6. PMID: 35104795.
    Citations: 2     Fields:    Translation:Humans
  8. Sloane KL, Miller JJ, Piquet A, Edlow BL, Rosenthal ES, Singhal AB. Prognostication in Acute Neurological Emergencies. J Stroke Cerebrovasc Dis. 2022 Mar; 31(3):106277. PMID: 35007934; PMCID: PMC8837701.
    Citations:    Fields:    Translation:HumansPHPublic Health
  9. Miller JJ. Targeting protein arginine methylation to death. Neuro Oncol. 2021 09 01; 23(9):1421-1422. PMID: 34037795; PMCID: PMC8408857.
    Citations:    Fields:    Translation:HumansCells
  10. Miller JJ, Fink A, Banagis JA, Nagashima H, Subramanian M, Lee CK, Melamed L, Tummala SS, Tateishi K, Wakimoto H, Cahill DP. Sirtuin activation targets IDH-mutant tumors. Neuro Oncol. 2021 01 30; 23(1):53-62. PMID: 32710757.
    Citations: 9     Fields:    Translation:Humans
  11. Miller JJ, Cahill DP. MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma. Neuro Oncol. 2020 11 26; 22(11):1553-1554. PMID: 32927482.
    Citations:    Fields:    Translation:HumansCells
  12. Tateishi K, Miyake Y, Kawazu M, Sasaki N, Nakamura T, Sasame J, Yoshii Y, Ueno T, Miyake A, Watanabe J, Matsushita Y, Shiba N, Udaka N, Ohki K, Fink AL, Tummala SS, Natsumeda M, Ikegaya N, Nishi M, Ohtake M, Miyazaki R, Suenaga J, Murata H, Aoki I, Miller JJ, Fujii Y, Ryo A, Yamanaka S, Mano H, Cahill DP, Wakimoto H, Chi AS, Batchelor TT, Nagane M, Ichimura K, Yamamoto T. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. Cancer Res. 2020 12 01; 80(23):5330-5343. PMID: 33067267.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  13. Richardson LG, Nieman LT, Stemmer-Rachamimov AO, Zheng XS, Stafford K, Nagashima H, Miller JJ, Kiyokawa J, Ting DT, Wakimoto H, Cahill DP, Choi BD, Curry WT. IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. Oncoimmunology. 2020 08 20; 9(1):1806662. PMID: 32923170.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  14. Nagashima H, Lee CK, Tateishi K, Higuchi F, Subramanian M, Rafferty S, Melamed L, Miller JJ, Wakimoto H, Cahill DP. Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells. Cancer Discov. 2020 11; 10(11):1672-1689. PMID: 32606138; PMCID: PMC7642007.
    Citations: 15     Fields:    Translation:HumansCells
  15. Youssef G, Miller JJ. Lower Grade Gliomas. Curr Neurol Neurosci Rep. 2020 05 22; 20(7):21. PMID: 32444979; PMCID: PMC7244462.
    Citations: 28     Fields:    Translation:Humans
  16. Miller JJ, Loebel F, Juratli TA, Tummala SS, Williams EA, Batchelor TT, Arrillaga-Romany I, Cahill DP. Accelerated progression of IDH mutant glioma after first recurrence. Neuro Oncol. 2019 05 06; 21(5):669-677. PMID: 30668823; PMCID: PMC6502499.
    Citations: 22     Fields:    Translation:Humans
  17. Tateishi K, Nakamura T, Juratli TA, Williams EA, Matsushita Y, Miyake S, Nishi M, Miller JJ, Tummala SS, Fink AL, Lelic N, Koerner MVA, Miyake Y, Sasame J, Fujimoto K, Tanaka T, Minamimoto R, Matsunaga S, Mukaihara S, Shuto T, Taguchi H, Udaka N, Murata H, Ryo A, Yamanaka S, Curry WT, Dias-Santagata D, Yamamoto T, Ichimura K, Batchelor TT, Chi AS, Iafrate AJ, Wakimoto H, Cahill DP. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clin Cancer Res. 2019 07 15; 25(14):4375-4387. PMID: 30975663; PMCID: PMC6924174.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  18. Juratli TA, Tummala SS, Riedl A, Daubner D, Hennig S, Penson T, Zolal A, Thiede C, Schackert G, Krex D, Miller JJ, Cahill DP. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. J Neurooncol. 2019 Jan; 141(2):327-335. PMID: 30536195; PMCID: PMC6924170.
    Citations: 27     Fields:    Translation:Humans
  19. Williams EA, Miller JJ, Tummala SS, Penson T, Iafrate AJ, Juratli TA, Cahill DP. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. Acta Neuropathol Commun. 2018 10 17; 6(1):106. PMID: 30333046.
    Citations: 13     Fields:    Translation:HumansCells
  20. Higuchi F, Fink AL, Kiyokawa J, Miller JJ, Koerner MVA, Cahill DP, Wakimoto H. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide. Mol Cancer Ther. 2018 12; 17(12):2551-2563. PMID: 30217967; PMCID: PMC6279590.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  21. Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, Fink AL, Baig A, Martinez-Lage M, Selig MK, Bihun IV, Shankar GM, Penson T, Lastrapes M, Daubner D, Meinhardt M, Hennig S, Kaplan AB, Fujio S, Kuter BM, Bertalan MS, Miller JJ, Batten JM, Ely HA, Christiansen J, Baretton GB, Stemmer-Rachamimov AO, Santagata S, Rivera MN, Barker FG, Schackert G, Wakimoto H, Iafrate AJ, Carter SL, Cahill DP, Brastianos PK. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018 11; 136(5):779-792. PMID: 30123936.
    Citations: 36     Fields:    Translation:HumansCells
  22. Shankar GM, Kirtane AR, Miller JJ, Mazdiyasni H, Rogner J, Tai T, Williams EA, Higuchi F, Juratli TA, Tateishi K, Koerner MVA, Tummala SS, Fink AL, Penson T, Schmidt SP, Wojtkiewicz GR, Baig A, Francis JM, Rinne ML, Batten JM, Batchelor TT, Brastianos PK, Curry WT, Barker FG, Jordan JT, Iafrate AJ, Chi AS, Lennerz JK, Meyerson M, Langer R, Wakimoto H, Traverso G, Cahill DP. Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8388-E8394. PMID: 30082399; PMCID: PMC6130372.
    Citations: 23     Fields:    Translation:HumansAnimals
  23. Miller JJ, Wick W. What's New in Grade II and Grade III Gliomas? Semin Neurol. 2018 02; 38(1):41-49. PMID: 29548051.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  24. Juratli TA, Thiede C, Koerner MVA, Tummala SS, Daubner D, Shankar GM, Williams EA, Martinez-Lage M, Soucek S, Robel K, Penson T, Krause M, Appold S, Meinhardt M, Pinzer T, Miller JJ, Krex D, Ely HA, Silverman IM, Christiansen J, Schackert G, Wakimoto H, Kirsch M, Brastianos PK, Cahill DP. Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget. 2017 Dec 12; 8(65):109228-109237. PMID: 29312603; PMCID: PMC5752516.
    Citations: 43     Fields:    
  25. Miller JJ, Shih HA, Andronesi OC, Cahill DP. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications. Cancer. 2017 Dec 01; 123(23):4535-4546. PMID: 28980701.
    Citations: 62     Fields:    Translation:Humans
  26. Tateishi K, Higuchi F, Miller JJ, Koerner MVA, Lelic N, Shankar GM, Tanaka S, Fisher DE, Batchelor TT, Iafrate AJ, Wakimoto H, Chi AS, Cahill DP. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. Cancer Res. 2017 08 01; 77(15):4102-4115. PMID: 28625978; PMCID: PMC5783559.
    Citations: 40     Fields:    Translation:HumansAnimalsCells
  27. Jordan JT, Miller JJ, Cushing T, Seijo M, Batchelor TT, Arrillaga-Romany IC, Shih HA, Nachtigall LB, Loeffler JS, Dietrich J. Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. Neurooncol Pract. 2018 Mar; 5(1):64-68. PMID: 31385986; PMCID: PMC6655410.
    Citations: 4     
  28. Alvarez-Breckenridge C, Miller JJ, Nayyar N, Gill CM, Kaneb A, D'Andrea M, Le LP, Lee J, Cheng J, Zheng Z, Butler WE, Multani P, Chow Maneval E, Ha Paek S, Toyota BD, Dias-Santagata D, Santagata S, Romero J, Shaw AT, Farago AF, Yip S, Cahill DP, Batchelor TT, Iafrate AJ, Brastianos PK. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. NPJ Precis Oncol. 2017; 1(1):5. PMID: 29872694; PMCID: PMC5871889.
    Citations: 28     
  29. Yáñez ML, Miller JJ, Batchelor TT. Diagnosis and treatment of epidural metastases. Cancer. 2017 04 01; 123(7):1106-1114. PMID: 28026861.
    Citations: 7     Fields:    Translation:Humans
  30. Miller JJ, Wen PY. Emerging targeted therapies for glioma. Expert Opin Emerg Drugs. 2016 Dec; 21(4):441-452. PMID: 27809598.
    Citations: 30     Fields:    Translation:HumansCells
  31. Miller JJ, Curry WT, Cahill DP, Dietrich J. Perspectives on investigational drugs and immunotherapies for glioblastoma. Expert Opin Investig Drugs. 2016 Sep; 25(9):1007-9. PMID: 27415034; PMCID: PMC5018991.
    Citations: 1     Fields:    Translation:Humans
  32. Olsen AL, Miller JJ, Bhattacharyya S, Voinescu PE, Klein JP. Cerebral perfusion in stroke-like migraine attacks after radiation therapy syndrome. Neurology. 2016 Feb 23; 86(8):787-9. PMID: 26819456.
    Citations: 4     Fields:    Translation:HumansPHPublic Health
  33. Miller JJ, Venna N, Siva A. Neuro-Behçet disease and autoinflammatory disorders. Semin Neurol. 2014 Sep; 34(4):437-43. PMID: 25369439.
    Citations: 3     Fields:    Translation:Humans
  34. Berkowitz AL, Baker JM, Miller JJ, Greenberg SM. Mystery case: cerebral amyloid angiopathy-related inflammation. Neurology. 2014 Oct 28; 83(18):1678-9. PMID: 25349274; PMCID: PMC4223081.
    Citations: 2     Fields:    Translation:Humans
  35. Sang L, Miller JJ, Corbit KC, Giles RH, Brauer MJ, Otto EA, Baye LM, Wen X, Scales SJ, Kwong M, Huntzicker EG, Sfakianos MK, Sandoval W, Bazan JF, Kulkarni P, Garcia-Gonzalo FR, Seol AD, O'Toole JF, Held S, Reutter HM, Lane WS, Rafiq MA, Noor A, Ansar M, Devi AR, Sheffield VC, Slusarski DC, Vincent JB, Doherty DA, Hildebrandt F, Reiter JF, Jackson PK. Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways. Cell. 2011 May 13; 145(4):513-28. PMID: 21565611; PMCID: PMC3383065.
    Citations: 336     Fields:    Translation:HumansAnimalsCells
  36. Torres JZ, Miller JJ, Jackson PK. High-throughput generation of tagged stable cell lines for proteomic analysis. Proteomics. 2009 May; 9(10):2888-91. PMID: 19405035.
    Citations: 73     Fields:    Translation:AnimalsCells
  37. Ban KH, Torres JZ, Miller JJ, Mikhailov A, Nachury MV, Tung JJ, Rieder CL, Jackson PK. The END network couples spindle pole assembly to inhibition of the anaphase-promoting complex/cyclosome in early mitosis. Dev Cell. 2007 Jul; 13(1):29-42. PMID: 17609108.
    Citations: 32     Fields:    Translation:HumansCells
  38. Hansen DV, Pomerening JR, Summers MK, Miller JJ, Ferrell JE, Jackson PK. Emi2 at the crossroads: where CSF meets MPF. Cell Cycle. 2007 Mar 15; 6(6):732-8. PMID: 17361104.
    Citations: 5     Fields:    Translation:AnimalsCells
  39. Miller JJ, Summers MK, Hansen DV, Nachury MV, Lehman NL, Loktev A, Jackson PK. Emi1 stably binds and inhibits the anaphase-promoting complex/cyclosome as a pseudosubstrate inhibitor. Genes Dev. 2006 Sep 01; 20(17):2410-20. PMID: 16921029; PMCID: PMC1560415.
    Citations: 107     Fields:    Translation:HumansCells
  40. Hao B, Zheng N, Schulman BA, Wu G, Miller JJ, Pagano M, Pavletich NP. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol Cell. 2005 Oct 07; 20(1):9-19. PMID: 16209941.
    Citations: 140     Fields:    Translation:HumansCells
  41. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, Conaway RC, Conaway JW, Harper JW, Pavletich NP. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature. 2002 Apr 18; 416(6882):703-9. PMID: 11961546.
    Citations: 667     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Miller's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (201)
Co-Authors (56)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.